Single-cell Omics Market Size & Share, by Product (Proteomics, Metabolomics, Transcriptomics); Application (Immunology, Neurology, Oncology, Cell Biology); End-user (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5060
  • Published Date: Jun 22, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Single-cell Omics Market size is poised to cross USD 30 Billion by the end of 2035, growing at a CAGR of approximately 22% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of single-cell omics was nearly USD 3 Billion.  Advancement in the studies of RNA sequencing is a major driver for the growth of the single-cell omics market. Since RNA sequencing provides a comprehensive snapshot of gene expression profiles in cells. By studying gene expression patterns at the single-cell level, researchers can identify and characterize distinct cell populations and subtypes within a tissue or organism. This has opened up new avenues for single-cell omics development.

Besides this, the rising investment in cell sequencing is also expected to augment the single-cell omics market growth. The National Institutes of Health (NIH) recently granted Texas A&M University System a USD 1.19 million grant for a collaboration between multiple disciplines to explore the deep links between genomes, nutrition, and health. The investment in cell sequencing is driven by the growing demand for single-cell omics research. Moreover, higher investment enables the development of innovative approaches for disease diagnosis, and therapeutic development.


Single-cell Omics Market
Get more information on this report: Request Free Sample PDF

Single-Cell Omics Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Instances of Cancer– Cancer is a complex disease that consists of diverse cell populations with distinct genetic and phenotypic profiles. Single-cell omics provide a powerful tool to segregate cancer cells. By analyzing individual cancer cells, researchers can identify rare cell populations that contribute to tumor development progression, and response to therapy.
  • Increasing Demand for Biologics– According to the Food and Drug Administration, the Center for Drug Evaluation and Research (CDER) authorized 37 innovative pharmaceuticals in 2022, either as new molecular entities (NMEs) through New Drug Applications (NDAs) or as new therapeutic biological products through Biologics License Applications (BLAs). Single-cell omics can aid in the section and optimization of cell aid in the selection and optimization of cell lines for biologics production.
  • Development of Innovative Products– CellenCHIP 384 for single-cell omics sample preparation was introduced as an essential component in the new cellenCHIP 384 by SCIENION and Cellenion. It expands the cellenONE's robotic capacity for miniaturization and high productivity operations. The field of single-cell omics is rapidly evolving, driven by continuous advancements in technologies and methodologies. These technological advancements attract researchers and fuel the demand for these innovative products.

Challenges

  • Single-Cell Omics Technique is Expensive- The need for specialized equipment, reagents, and data analysis resources adds to the overall cost. Affordability and cost-effectiveness of single-cell omics technologies are significant considerations for their widespread implementation, especially in resource-limited settings or for small research institutes.
  • Technical Complications Associated with the Research
  • Lack of Standardized Protocols and Benchmark Datasets

Single-cell Omics Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~22%

Base Year Market Size (2022)

~ USD 3.0 Billion

Forecast Year Market Size (2035)

~ USD 30.0 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Single-Cell Omics Segmentation

Application (Immunology, Neurology, Oncology, Cell Biology)

In 2035, the oncology sector is estimated to account for 46% share of the global single-cell omics market. Moreover, it garnered a revenue share of around 45% in 2022.  The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. As of 2022, over 770 of the over 1,200 active clinical studies for cell and gene therapies were in oncology. Single-cell omics enable the identification of specific gene expression patterns or genetic alterations associated with therapeutic response or resistance. By profiling individual cancer cells, researchers can identify biomarkers that predict the likelihood of response to gene therapy. Furthermore, rising investment in cancer treatment has driven the segment’s growth. By building state-of-the-art cancer treatment centers and ensuring proper testing, screening, and treatment of cancers impacted by the COVID-19 pandemic, the Australian Government is investing USD 614 million in services

End User (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals)

The research organization segment  is projected to hold around 55% share of the global single-cell omics market in the year 2035. The segment will expand at a notable CAGR over the projected time period. Rising investment by private sectors to accelerate the research in the research facilities. For instance, Schmidt Futures allocated USD 550 million to the latest research facility aimed at growing single-cell proteomics technologies in March 2023. Increased investment in research facilities allows for the establishment of advanced infrastructure dedicated to single-cell omics research. This includes the procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms.

Our in-depth analysis of the global single-cell omics market includes the following segments:

           Application

  • Immunology
  • Neurology
  • Oncology
  • Cell Biology

           Product

  • Proteomics
  • Metabolomics
  • Transcriptomics

             End User

  • Pharmaceutical & Biotechnology Companies
  • Research Organization
  • Hospitals
 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Single-cell Omics Industry- Regional Synopsis

North American Market Forecast

The North America single-cell omics market held over 46% of the revenue share in 2022 and is projected to be the largest with a share of about nearly 40% by the end of 2035. The growth of the market is credited to rising investment in advanced healthcare technologies. Approximately USD 31 billion was invested in healthcare technology enterprises in the United States in the first quarter of 2022, which represents 28% of total investments. Investments in healthcare technologies, such as genomics, molecular diagnostics, and bioinformatics, support the development of precision medicine approaches. The integration of single-cell omics with healthcare technologies enables more accurate disease characterization, and patient stratification, driving the demand for single-cell omics technologies in the region.  

APAC Market Statistics

The Asia Pacific single-cell omics market is expected to be the second largest, with a share of over 27% by the end of 2035, rising at a CAGR of almost 18% over the anticipated period. The rise in the collaboration of companies will bring new opportunities for market growth. For instance, Mission Bio, an innovator in high-throughput single-cell DNA and multi-omics analysis, recently signed a collaboration contract with SequMed, a Chinese pioneer in single-cell omics technology invention and applications. The partnership will allow Mission Bio's technological platform to be combined the clinical assay development and data analysis capabilities of SequMed in order to jointly create advanced single-cell assays for cancer detection, medication counseling, and prognostic tracking in China.

 

Research Nester
Single-cell Omics Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Single-cell Omics Market

top-features-companies
    • Ultima Genomics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • 10x Genomics, Inc.
    • Becton, Dickinson and Company (BD)
    • CELLENION
    • PerkinElmer Inc.
    • ANGLE plc
    • Illumina, Inc.
    • Bio-Rad Laboratories, Inc.
    • Mission Bio, Inc.
    • Standard BioTools Inc.

In-the-news

In The News

  • Ultima Genomics, Inc. announced the partnership with 10x Genomics. With this collaboration, the ultra-high throughput sequencing systems will be using chromium single-cell gene expression solutions of 10X Genomics. Both organizations will give researchers optimized, cost-effective methods to enable larger-scale gene expression analysis in single cells.
  • Mission Bio, Inc. collaborated with Fulent Genetics. By the help of Mission Bio, Fulgent Genetics will be able to offer Pharma drug developers single-cell multi-omics for biomarker identification, clinical research, and single-cell MRD creation at large scale

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5060
  • Published Date: Jun 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of cancer, rising investment in cell therapy, and technological advancement of single-cell techniques are the major factors driving the market growth.

The market size of single-cell omics is anticipated to attain a CAGR of around 22% over the forecast period, i.e., 2023 – 2035.

The major players in the market are 10x Genomics, Inc., Becton, Dickinson and Company (BD), CELLENION, PerkinElmer Inc., ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., Mission Bio Inc., Standard BioTools Inc. and Ultima Genomics, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, product, end user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

There is no standardization and the higher cost of single-cell omics is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Single-cell Omics Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying